Identification of enhanced IFN-γ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry by Throm, Allison A et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
8-9-2018 
Identification of enhanced IFN-γ signaling in polyarticular juvenile 
idiopathic arthritis with mass cytometry 
Allison A Throm 
Halima Moncrieffe 
Amir B Orandi 
Jeanette T Pingel 
Theresa L Geurs 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Allison A Throm, Halima Moncrieffe, Amir B Orandi, Jeanette T Pingel, Theresa L Geurs, Hannah L Miller, 
Allyssa L Daugherty, Olga N Malkova, Daniel J Lovell, Susan D Thompson, Alexei A Grom, Megan A 
Cooper, Stephen T Oh, and Anthony R French 
Identification of enhanced IFN-g  signaling in
polyarticular juvenile idiopathic arthritis with
mass cytometry
Allison A. Throm, … , Stephen T. Oh, Anthony R. French
JCI Insight. 2018;3(15):e121544. https://doi.org/10.1172/jci.insight.121544.
  
Polyarticular juvenile idiopathic arthritis (JIA) is among the most challenging of the JIA
subtypes to treat. Even with current biologic therapies, the disease remains difficult to
control in a substantial subset of patients, highlighting the need for new therapies. The aim
of this study was to use the high dimensionality afforded by mass cytometry with phospho-
specific antibodies to delineate signaling abnormalities in immune cells from treatment-
naive polyarticular JIA patients. Peripheral blood mononuclear cells were isolated from 17
treatment-naive polyarticular JIA patients, 10 of the patients after achieving clinical
remission, and 19 healthy controls. Samples were stimulated for 15 minutes with IL-6 or
IFN-g and analyzed by mass cytometry. Following IFN-g stimulation, increased STAT1
and/or STAT3 phosphorylation was observed in subsets of CD4 T cells and classical
monocytes from treatment-naive patients. The enhanced IFN-g signaling was associated
with increased expression of JAK1 and SOCS1 in CD4 T cells. Furthermore, substantial
heterogeneity in surface marker expression was observed among the subsets of CD4 T
cells and classical monocytes with increased IFN-g responsiveness. The identification of
enhanced IFN-g signaling in CD4 T cells and classical monocytes from treatment-naive
polyarticular JIA patients provides mechanistic support for investigations into therapies that
attenuate IFN-g signaling in this disease.
Research Article Immunology Inflammation
Find the latest version:
http://jci.me/121544/pdf
1insight.jci.org   https://doi.org/10.1172/jci.insight.121544
R E S E A R C H  A R T I C L E
Conflict of interest: The authors have 
declared that no conflict of interest 
exists.
Submitted: April 9, 2018 
Accepted: June 28, 2018 
Published: August 9, 2018
Reference information: 
JCI Insight. 2018;3(15):e121544. 
https://doi.org/10.1172/jci.
insight.121544.
Identification of enhanced IFN-γ signaling 
in polyarticular juvenile idiopathic arthritis 
with mass cytometry
Allison A. Throm,1,2 Halima Moncrieffe,3,4 Amir B. Orandi,1 Jeanette T. Pingel,1 Theresa L. Geurs,1 
Hannah L. Miller,5 Allyssa L. Daugherty,1 Olga N. Malkova,6 Daniel J. Lovell,7 Susan D. Thompson,3 
Alexei A. Grom,7 Megan A. Cooper,1 Stephen T. Oh,6,8 and Anthony R. French1,2,5
1Division of Pediatric Rheumatology, Department of Pediatrics, Washington University School of Medicine, St. Louis, 
Missouri, USA. 2Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri, USA. 
3Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA. 
4Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, Ohio. 5Department of Pathology and 
Immunology and 6The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, 
Washington University School of Medicine, St. Louis, Missouri, USA. 7Division of Rheumatology, Cincinnati Children’s 
Hospital Medical Center, Cincinnati, Ohio, USA. 8Division of Hematology, Department of Internal Medicine, Washington 
University School of Medicine, St. Louis, Missouri, USA.
Introduction
Polyarticular juvenile idiopathic arthritis (JIA) represents a subset of  JIA patients with arthritis involving 
5 or more joints, beginning before 16 years of  age, without features of  psoriatic arthritis or a spondyloar-
thropathy. Polyarticular JIA constitutes approximately 15%–25% of  JIA patients and can be further subdi-
vided based on the presence or absence of  rheumatoid factor (RF) (1, 2). The incidence of  polyarticular JIA 
in the US has been reported to be 2 per 100,000 people (3). Polyarticular JIA inflicts significant morbidity 
on children, including joint limitation and/or destruction. For example, a high percentage of  hand and 
wrist x-rays from polyarticular JIA patients identify abnormalities at the time of  diagnosis (4), and 50% of  
patients manifest evidence of  radiographic progression within 2 years of  diagnosis (5).
Prior to the advent of  biologic agents, polyarticular JIA was often refractory to therapy, with only 
6%–23% of  patients achieving long-term remission at 10 years (6, 7) and with those with RF+ polyarticu-
lar JIA being the least likely to sustain remission off  medications of  all JIA subsets (8). Even with modern 
biologic therapies, a significant fraction of  polyarticular JIA patients have persistent disease activity (9). 
RF+ polyarticular JIA patients in particular have lower response rates to treatment and longer times to 
clinical remission, with higher rates of  disease flare (8, 10, 11). Together, these observations suggest mech-
anistic differences in polyarticular JIA compared with other JIA subsets.
Polyarticular juvenile idiopathic arthritis (JIA) is among the most challenging of the JIA subtypes to 
treat. Even with current biologic therapies, the disease remains difficult to control in a substantial 
subset of patients, highlighting the need for new therapies. The aim of this study was to use the 
high dimensionality afforded by mass cytometry with phospho-specific antibodies to delineate 
signaling abnormalities in immune cells from treatment-naive polyarticular JIA patients. Peripheral 
blood mononuclear cells were isolated from 17 treatment-naive polyarticular JIA patients, 10 of 
the patients after achieving clinical remission, and 19 healthy controls. Samples were stimulated 
for 15 minutes with IL-6 or IFN-γ and analyzed by mass cytometry. Following IFN-γ stimulation, 
increased STAT1 and/or STAT3 phosphorylation was observed in subsets of CD4 T cells and classical 
monocytes from treatment-naive patients. The enhanced IFN-γ signaling was associated with 
increased expression of JAK1 and SOCS1 in CD4 T cells. Furthermore, substantial heterogeneity in 
surface marker expression was observed among the subsets of CD4 T cells and classical monocytes 
with increased IFN-γ responsiveness. The identification of enhanced IFN-γ signaling in CD4 T cells 
and classical monocytes from treatment-naive polyarticular JIA patients provides mechanistic 
support for investigations into therapies that attenuate IFN-γ signaling in this disease.
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Overall, the etiology of  JIA is not well characterized. Siblings of  patients with JIA are over 15-fold 
more likely to develop JIA than the general population (12), with monozygotic twins having an even high-
er concordance rate of  25%–40% for JIA (13), implicating a genetic component to the disease. However, 
minimal evidence exists for a Mendelian pattern of  inheritance, suggesting that JIA is a complex disorder 
associated with multiple genes. The strongest genetic association is with HLA alleles (1, 2), accounting for 
13%–20% of  the sibling concurrence risk in JIA and implicating T cell involvement in disease (12, 14). Fur-
thermore, cellular infiltrates in affected joint synovium are enriched for T cells as well as B cells and mac-
rophages (1). There is also accumulating evidence that innate immune responses contribute to the onset of  
polyarticular JIA (15–18). For example, a study of  transcriptional profiles of  peripheral blood mononuclear 
cells (PBMCs) from polyarticular JIA patients (prior to therapy with methotrexate or biologic agents) iden-
tified the upregulation of  monocyte-associated and plasmacytoid dendritic cell–associated genes in subsets 
of  polyarticular JIA patients (19).
The strong upregulation of  inflammatory cytokines in polyarticular JIA patients has provided addi-
tional insight into the pathogenesis of  polyarticular JIA. IL-6 is upregulated in the sera and synovial fluid 
of  polyarticular JIA patients and correlates with severity of  joint involvement and inflammatory markers 
(20). A multiplex survey of  30 cytokines and chemokines in the plasma and synovial fluid of  polyarticular 
JIA patients demonstrated that IL-1, IL-6, IFN-γ, and, to a lesser extent, TNF-α were strongly upregulat-
ed in the plasma of  polyarticular JIA patients with active compared with quiescent disease (21). Biologic 
agents specifically targeting IL-1, IL-6, and TNF-α have been shown to be efficacious in treating polyarticu-
lar JIA in randomized controlled trials (22–27), highlighting the importance of  inflammatory cytokines in 
the pathogenesis of  polyarticular JIA.
Despite the insights gained in previous studies and the success of  a number of  biologic agents that 
block proinflammatory cytokines, a subset of  polyarticular JIA patients have difficult to control, refractory 
disease. Therefore, to further investigate potential immune cell signaling perturbations in polyarticular JIA 
patients, we performed mass cytometry on PBMCs from treatment-naive polyarticular JIA patients and 
controls. By coupling the deep profiling allowed by mass cytometry with multiparameter phospho-specific 
antibodies, we were able to probe the activation state of  14 signaling molecules in 13 distinct leukocyte 
subsets within single patient samples both at baseline and following perturbations with IFN-γ or IL-6. This 
approach identified enhanced IFN-γ responsiveness in subsets of  CD4 T cells and monocytes from treat-
ment-naive polyarticular JIA patients.
Results
Patient cohort. Samples from 17 treatment-naive polyarticular JIA patients, 10 of  the 17 JIA patients while 
in clinical remission on medication, and 19 controls were analyzed (Table 1). Patients who had either not 
achieved clinical remission at the time of  the analysis or for whom follow-up samples were not available 
were not included in the assessment of  samples in clinical remission on medication. The age of  the patients 
and controls in the cohort was well matched with a mean patient age of  11.6 years and mean control age of  
11.7 years. 52.9% of  the patients were female, while 73.7% of  the controls were female.
Immune cell percentages. Mass cytometry was used to assess the distribution of  distinct groups of  immune 
cells in the peripheral blood of  treatment-naive polyarticular JIA patients and healthy controls as well as a 
subset of  the polyarticular JIA patients in clinical remission on medication. Individual samples were debar-
coded and gated for live immune cell singlets (Supplemental Figure 1; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.121544DS1). Specific immune cell types were 
identified based on surface marker expression (Supplemental Table 4). No significant differences were iden-
tified in the distribution of  any immune cell types when comparing treatment-naive patients and controls 
(Figure 1A). There were also no differences in cell populations detected when treatment-naive patients and 
remission patients were examined in aggregate or in paired treatment-naive and remission patient samples 
(Figure 1B). Of  note, percentages of  immune cell subtypes were compared rather than absolute cell counts, 
because cell counts were not available for the control samples.
Signaling phenotype. After examining differences in immune cell frequency between treatment-naive 
polyarticular JIA patients and matched controls, the baseline signaling state and signaling potential of  
immune cells from treatment-naive polyarticular JIA patients and matched controls was assessed. We first 
demonstrated that the basal and stimulated phosphorylation states of  a panel of  14 signaling proteins fol-
lowing stimulation with 5 different cytokines were not significantly perturbed by cyropreservation during 
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sample processing of  a single donor (Supplemental Figure 2). To select appropriate stimuli for analysis of  
polyarticular JIA patients, a preliminary experiment was conducted with a single treatment-naive polyartic-
ular JIA patient with 8 different cytokines (Supplemental Figure 3). We saw expected patterns of  phosphor-
ylation with specific cytokine stimulation. Given limitations in cell numbers, we elected to prioritize IFN-γ 
and IL-6 stimulation based on prior work demonstrating that IFN-γ and IL-6 were the most significantly 
elevated cytokines in the sera of  polyarticular JIA patients (21). Due to cell number limitations, not all 
patient and control samples underwent stimulation with IL-6 or IFN-γ (Supplemental Table 3).
Citrus was used to quantify stratifying differences (i.e., differences that distinguish patients from con-
trols) in signaling phenotype between treatment-naive patients and controls (or remission patients). Citrus is 
an analytical technique which combines hierarchical clustering of  cells based on surface marker expression 
with an analysis of  stratifying features (e.g., the signaling differences) that distinguish the two compared 
groups (i.e., patients and controls). As not all cells in a given population may be responding, Citrus allows 
for the analysis of  subsets of  cell populations (e.g., CD4 T cells) without the biases of  manual gating. Citrus 
detected no distinguishing signaling differences at baseline or with IL-6 stimulation between treatment-na-
ive patients and controls or remission patients. Differences were detected with IFN-γ stimulation between 
treatment-naive patients and controls as well as between treatment-naive patients and remission patients 
(Figure 2 and Supplemental Figures 4–6). Specifically, treatment-naive patients phosphorylated STAT3 in 
classical monocyte clusters (CD14+CD16–HLA-DR+) and STAT1 and STAT3 in naive CD4 T cell clusters 
more strongly than controls (Figure 2). Stronger STAT3 phosphorylation in treatment-naive patients than 
controls was also detected on canonically gated classical monocytes via analysis with significance analysis 
of  microarrays (SAM) (Supplemental Figure 7).
Citrus utilizes unsupervised hierarchical clustering based on surface markers, allowing distinct immune 
cell types to be partitioned into different parts of a hierarchical tree, facilitating analysis of stratifying charac-
teristics of the immune cell subsets between the two groups of interest (Figure 2A and Supplemental Figure 
4). There was substantial heterogeneity within the naive CD4 population and, to a lesser extent, in the clas-
sical monocytes in subsets of cells with increased IFN-γ responsiveness. To investigate differences in surface 
marker expression that distinguished the subsets of cells with more robust responses to IFN-γ in the patients 
compared with controls, trios of connected clusters in which two clusters were stratifying (between patients 
Table 1. Patient demographics and medications
Patients Sex Age at sample 
collection (yr)
RF CCP ESR (mm/h) CRP (mg/l) Age at remission 
(yr)
Medications at 2nd draw Control Research 
siteA
1 F 13.9 + + 27 10.6 15 MTX, Plaquenil 15 yr F 1
2 F 10.3 – – 85 138 12 MTX, Daypro 11.7 yr F 1
3 F 11.7 + – 9 4.5  12 MTX, Enbrel 11.7 yr F 1
4 M 15 + + 24 ND 16 MTX, Enbrel 17 yr M 1
5 M 15 + + 14 12.2 16 MTX, Enbrel 17 yr M 1
6 M 4 – nd 38 25.1 5 MTX, Enbrel 3 yr M 1
7 F 16.9 + + 57 24.7 19 yr F 1
8 F 7.2 + – 9 4 10.1 yr F 1
9 M 14.2 – – 18 ND 15.7 yr M 1
10 F 1.5 – nd NA NA 1.8 MTX 1.2 yr F 2
11 F 14.6 – nd NA NA 15.3 MTX 15.4 yr F 2
12 F 11.3 – nd NA NA 11.1 yr F 2
13 M 15.2 – nd NA NA 9.4 yr F 2
14 F 15.8 – nd NA NA 16.3 MTX, adalimumab 12.8 yr F 2
15 M 8.8 – nd NA NA 9.3  MTX, tocilizumab 8.2 yr F 2
16 M 20.6 – nd NA NA 5.1 yr F 2
17 M 1.4 – nd NA NA 4.7 yr M 2
18 13.4 yr F 1
19 12.6 yr F 1
MTX, methotrexate; RF, rheumatoid factor; CCP, anti-cyclic citrullinated peptide; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ND, no data; 
NA, not available. AResearch sites: 1 denotes St. Louis Children’s Hospital and 2 denotes Cincinnati Children’s Hospital.
4insight.jci.org   https://doi.org/10.1172/jci.insight.121544
R E S E A R C H  A R T I C L E
and controls for both phosphorylated STAT1 [p-STAT1] and p-STAT3 in CD4 T cells) and one nonstratifying 
were examined. Comparisons of these trios in proximal (larger clusters) and distal (smaller clusters) parts of  
the tree were performed (using ANOVA with a Dunnett’s post hoc test). When examining a larger, proximal 
CD4 cluster, the stratifying CD4 T cells had higher expression of CD11c, CD45RA (marker of naive T cells), 
and CD38 than the nearest nonstratifying clusters (Figure 3, A and B). When examining a smaller, more distal 
trio, CD45RA, CD38, and CD27 had higher expression in stratifying than nonstratifying clusters (Figure 3, A 
and C). A global assessment of surface marker expression patterns of stratifying and nonstratifying naive CD4 
T cell clusters demonstrated that all stratifying clusters expressed CD3, CD4, and CD27, with variations in 
expression levels of CD4 and CD27 (Supplemental Figure 4 and Supplemental Figure 8). All stratifying clus-
ters were CD45RA+ and CD38+, with CD45RA intensity decreasing and CD38 intensity increasing as clusters 
were divided into smaller, more specific subsets from larger clusters (Supplemental Figure 4 and Supplemental 
Figure 8). All stratifying clusters were CD8–, CD45ROlo or CD45RO–, and CD56– (Supplemental Figure 4). 
Comparison of surface marker intensity of all stratifying to all nonstratifying naive CD4 T cell clusters revealed 
a wide heterogeneity in expression of CD4, CD45RA, CD27, CD38, and HLA-DR (Supplemental Figure 8).
Heterogeneity was also observed in the stratifying classical monocyte clusters. Trios of  two strat-
ifying (between patients and controls for p-STAT3) clusters and one nonstratifying monocyte clus-
ter revealed distinct stratifying monocyte subsets on different branches of  the monocyte portion of  
the tree (Figure 4). In one branch of  the tree, stratifying monocyte subsets had higher expression of  
CD45RA and HLA-DR and lower expression of  CD45RO than nonstratifying clusters (Figure 4, A 
and B). On the other branch of  the monocyte part of  the tree, the nonstratifying cluster was lower in 
CD45RA, CD45RO, and CD11b than the largest stratifying monocyte clusters (Figure 4, A and C). 
Figure 1. No differences were identified in the percentage of different cell types between treatment-naive patients and matched controls or in paired 
patient samples with the cessation of disease. (A) Treatment-naive patient versus matched control peripheral blood mononuclear cell (PBMC) percentag-
es (1-way ANOVA [F = 52.94, P < 0.0001] with Bonferroni’s multiple comparisons test; for pairwise comparisons, P > 0.05; n = 17 treatment-naive patients 
and 19 controls). Data represent mean ± SEM. (B) Differences for PBMC percentage in paired treatment-naive and remission patient samples (13 paired 
2-tailed t tests with Benjamini Hochberg multiple hypothesis correction; P > k/n × 0.05 for all comparisons, where k is the ranking from 1 to 13 of the 13 P 
values from lowest to highest and n is the total number of hypotheses tested (n = 13); n = 7 paired treatment-naive and remission patient samples).
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All monocyte clusters were CD14+, CD11c+, and CD38+ and CD4lo and lacked expression of  CD8 
and CD16 (Supplemental Figure 4 and Supplemental Figure 9). Comparing all stratifying to all non-
stratifying classical monocyte clusters for surface marker intensity revealed trends in higher levels of  
median CD4, CD45RA, and HLA-DR intensity and lower levels of  CD45RO intensity in stratifying 
than nonstratifying clusters (Supplemental Figure 9).
Similar signaling differences with IFN-γ stimulation were observed between treatment-naive patients 
and remission patients (Supplemental Figure 5 and Supplemental Figure 6). With IFN-γ stimulation, 
STAT3 was more strongly phosphorylated in some CD4 T cell clusters and STAT1 was more strongly 
phosphorylated in some classical monocyte clusters in treatment-naive patients in comparison to remis-
sion patients (Supplemental Figure 5, A–C). Trends toward decreasing p-STAT1 in classical monocytes 
and p-STAT3 in CD4 T cells were also observed paired treatment-naive and remission patient samples 
(Supplemental Figure 5D).
Figure 2. Classical monocyte and CD4 T cell subsets respond more strongly to IFN-γ stimulation in treatment-naive patients than controls with 
enhanced STAT1 and STAT3 phosphorylation. (A) Hierarchical clustering for IFN-γ–stimulated treatment-naive patient versus control PBMCs. Nonstrat-
ifying clusters are light blue for FDR < 0.05, p-STAT1 stratifying (different between patients and controls for a signaling molecule) clusters are purple, 
p-STAT3 stratifying clusters are orange, and clusters stratifying for both p-STAT1 and p-STAT3 are red. Asterisks indicate clusters visualized in C. (B) 
Heatmap depicting surface marker intensities for stratifying and nonstratifying classical monocyte and CD4 T cell clusters. (C) Arcsinh-transformed medi-
an phosphoprotein intensities for largest stratifying CD4 T cell and classical monocyte clusters (classical monocyte p-STAT1: t = 1.656, df = 32, P = 0.108; 
classical monocyte p-STAT3: t = 2.72, df = 32, P = 0.011; CD4 T cell p-STAT1: t = 3.04, df = 21, P = 0.006; CD4 T cell p-STAT3: t = 3.40, df = 32, P = 0.002). 
White circles denote treatment-naive patients, and black squares denote controls. Data represent mean ± SEM. n = 15 IFN-γ–stimulated treatment-naive 
patients, patients 4 and 5 in Table 1 did not have enough cells for an IFN-γ–stimulated sample and were excluded here; n = 19 controls. Statistical signifi-
cance was determined with 2-tailed Student’s t test with Benjamini-Hochberg multiple hypothesis correction to account for 4 comparisons.
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Figure 3. Heterogeneity in the naive CD4 T cells with enhanced responsiveness to IFN-γ stimulation in polyarticular JIA patients. (A) Schematic of hier-
archical clustering computed by Citrus, with clusters analyzed in B and C denoted by boxes. Nonstratifying clusters between patient and control samples 
are light blue for FDR < 0.05, p-STAT1 stratifying (different between patient and control samples in regard to the phosphorylation of a specific signaling 
molecule) clusters are purple, p-STAT3 stratifying clusters are orange, and clusters stratifying for both p-STAT1 and p-STAT3 are red. (B) CD11c, CD45RA, 
and CD38 arcsinh-transformed medians in 3 proximal nodes in the CD4 T cell branch of clustering tree (ANOVA with Dunnett’s post hoc, *P < 0.05). Data 
represent mean ± SEM. (C) CD27, CD45RA, and CD38 arcsinh-transformed medians in 3 distal nodes in the CD4 T cell branch of clustering tree (ANOVA with 
Dunnett’s post hoc, *P < 0.05). Data represent mean ± SEM. n = 15 IFN-γ–stimulated treatment-naive patients, patients 4 and 5 in Table 1 did not have 
enough cells for an IFN-γ–stimulated sample and were excluded here; n = 19 controls.
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Differences in expression of  components of  the IFN-γ signaling cascade. Given the differences observed in 
patient and control CD4 T cell and classical monocyte signaling responses, further investigation into the 
mechanisms contributing to differences in IFN-γ signaling was performed. Flow cytometry evaluation 
of  targeted components of  the IFN-γ signaling pathway was performed on 6 treatment-naive patients 
and 4 controls for whom samples were available. (Of  note, half  of  these 6 patients had only a modest 
response to IFN-γ stimulation in the mass cytometry experiments.) PBMCs were stained for naive CD4 
T cell or classical monocyte markers as well as p-STAT1, p-STAT3, JAK1, SOCS1, protein inhibitor of  
activated STAT1 (PIAS1), and IFN-γ receptor 1 (IFNGR1) in 4 separate flow cytometry panels (Supple-
mental Table 2). Both p-STAT1 and p-STAT3 were higher in patient compared with control naive CD4 
T cells at baseline and following IFN-γ stimulation (Figure 5A). There was no difference in IFNGR1 
expression between patient and control naive CD4 T cells (Figure 5B); however, JAK1 expression was 
higher in treatment-naive patient than control naive CD4 T cells (Figure 5C), suggesting that increased 
JAK1 expression may contribute to increased IFN-γ responsiveness. There was also higher expression 
of  the inhibitory protein SOCS1 (but not PIAS1) in treatment-naive patient compared with control 
CD4 T cells (Figure 5D), consistent with its induction by IFN-γ as a negative regulator (28). No statis-
tically significant differences were detected between patient and control classical monocytes in any of  
the examined IFN-γ signaling cascade components, perhaps reflecting the small sample size evaluated 
(Supplemental Figure 10).
Function in relation to phenotype. Further investigations were performed to determine whether the 
observed increased IFN-γ responsiveness correlated with increased naive CD4 T cell and classical mono-
cyte proliferation in treatment-naive JIA patients. Higher levels of  proliferation (analyzed as Ki-67 expres-
sion) were observed in treatment-naive patient classical monocytes and naive CD4 T cells compared with 
controls (Supplemental Figure 11, A and B), supporting a potential association between IFN-γ respon-
siveness and proliferation in treatment-naive JIA patients. Interestingly, both stratifying and nonstratifying 
patient classical monocytes and T cells were proliferating more than the same subsets from controls (Sup-
plemental Figure 11, C and D).
Discussion
Despite a large number of  studies focused on polyarticular JIA, the pathogenesis of  this disorder is 
still poorly understood. This study sought to delineate signaling differences in peripheral immune cells 
between treatment-naive polyarticular JIA patients and controls using the high-dimensional capabilities 
of  mass cytometry coupled with multiparameter phospho-specific antibodies. No significant differences 
were detected in basal signaling (unstimulated) or following IL-6 stimulation between treatment-naive JIA 
patients and controls (or remission patients). However, enhanced responsiveness to IFN-γ stimulation was 
observed with increased STAT1 and/or STAT3 phosphorylation in subsets of  CD4 T cells and classical 
monocytes from treatment-naive JIA patients compared with controls. This enhanced responsiveness to 
IFN-γ correlated with increased expression of  JAK1 and SOCS1 in CD4 T cells from treatment-naive JIA 
patients compared with controls.
No statistically significant perturbations in the percentages of  different immune cells were observed 
between treatment-naive patients and controls or paired treatment-naive and remission patient samples. 
However, there was a trend toward an increase in the percentage of  NK cells with cessation of  active dis-
ease in the paired individual treatment-naive and remission patient samples (Figure 1B; t statistic [t] = 3.63, 
degrees of  freedom [df] = 8, P = 0.007).
Unstimulated treatment-naive patients and controls did not have significantly different basal phos-
phorylation patterns in the mass cytometry analysis, despite reported elevated levels of  IFN-γ, IL-6, 
and IL-1 in polyarticular JIA patient sera (21). This was unexpected given that baseline differences in 
Figure 4. Heterogeneity in the classical monocytes with enhanced responsiveness to IFN-γ stimulation in polyarticular JIA patients. (A) Schematic of 
hierarchical clustering computed by Citrus, with clusters analyzed in B and C denoted by boxes. Nonstratifying clusters between patient and control sam-
ples are light blue for FDR < 0.05, p-STAT1 stratifying (different between patient and control samples in regard to the phosphorylation of a specific) clus-
ters are purple, p-STAT3 stratifying clusters are orange, and clusters stratifying for both p-STAT1 and p-STAT3 are red. (B) CD45RA, CD45RO, and HLA-DR 
arcsinh-transformed medians in one branch of monocytes in hierarchical clustering tree (ANOVA with Dunnett’s post hoc, *P < 0.05). Data represent mean 
± SEM. (C) CD45RA, CD45RO, and CD11b arcsinh-transformed medians in other branch of monocytes in hierarchical clustering tree (ANOVA with Dunnett’s 
post hoc, *P < 0.05). Data represent mean ± SEM. n = 15 IFN-γ–stimulated treatment-naive patients, patients 4 and 5 in Table 1 did not have enough cells 
for an IFN-γ–stimulated sample and were excluded here; n = 19 controls.
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gene expression profiles have been reported in treatment-naive polyarticular JIA patients compared 
with healthy controls (16, 29). However, other studies of  unstimulated autoimmune patient PBMCs 
compared with controls have also not detected baseline differences in phosphorylation of  signaling 
molecules, including p-STAT1 and p-STAT2 in Addison’s disease (30), p-ZAP70 in type 1 diabetes (31), 
and p-STAT1 in systemic JIA (32, 33). The lack of  differences in basal phosphorylation may be due to 
sample processing. We evaluated parallel fresh and frozen samples from a single donor and demonstrat-
ed that cryopreservation did not affect phosphoprotein status in either unstimulated or cytokine-stim-
ulated conditions; however, it is possible that cell processing (and removal from the serum cytokine 
milieu) itself  alters baseline phosphorylation. The potential effect of  sample processing on basal levels 
of  phosphoproteins is consistent with previous work demonstrating differences in gene expression pro-
files of  PBMCs after 4 hours of  processing delay (34).
Signaling differences were detected between IFN-γ–stimulated treatment-naive JIA patient and control 
PBMCs. Naive CD4 T cells more strongly phosphorylated STAT1 and STAT3, while classical monocytes 
demonstrated enhanced phosphorylation of  STAT3 following 15 minutes of  IFN-γ stimulation of  sam-
ples from treatment-naive JIA patients compared with controls. The variation observed in p-STAT1 and 
p-STAT3 in the treatment-naive patients was not correlated with RF status (Supplemental Figure 12). Sig-
naling differences were also detected in these cell types when comparing treatment-naive and remission 
samples. These observations about enhanced responsiveness to IFN-γ stimulation are supported by prior 
whole blood expression profiling studies of  treatment-naive polyarticular JIA patients, which found evi-
dence of  alterations in the STAT1-3/IFN response factor–mediated pathways using Ingenuity Pathway 
Analysis (29). Aberrant STAT3 regulation has also been inferred from pathway analysis of  CD4 T cells 
from patients with active rheumatoid arthritis, a disease with some similarities with polyarticular JIA (35, 
36). In contrast, monocytes from patients with active systemic JIA, a different subtype of  JIA with an 
autoinflammatory phenotype, have been shown to have defective STAT1 phosphorylation following IFN-γ 
stimulation and elevated SOCS1 transcript expression levels (33) as well as a restricted IFN-γ–induced 
genetic signature and minimal upregulation of  IFN-γ–induced chemokines (32).
Figure 5. Signaling differences between naive CD4 T cells from treatment-naive patients and controls detected by mass cytometry are associated 
with higher levels of JAK1 and SOCS1 in patient naive CD4 T cells. (A) Differences in STAT1 phosphorylation (unstimulated: 2-tailed t = 2.71, df = 8, 
P = 0.027; stimulated: t = 1.44, df = 8, P = 0.19) and STAT3 phosphorylation (unstimulated: t = 3.24, df = 8, P = 0.012; stimulated: t = 3.91, df = 8, P = 
0.005) in patient and control naive CD4 T cells with and without 250 ng/ml IFN-γ stimulation for 15 minutes. (B) IFN-γ receptor 1 (IFNGR1) in unstim-
ulated patient and control naive CD4 T cells (t = 1.40, df = 8, P = 0.20). (C) JAK1 in unstimulated patient and control naive CD4 T cells (t = 2.56, df = 8, 
P = 0.034). (D) Inhibitory molecules SOCS1 (left) and protein inhibitor of activated STAT1 (PIAS1) (right) in unstimulated patient and control naive CD4 
T cells (SOCS1: t = 2.78, df = 8, P = 0.024, PIAS1: t = 1.89, df = 8, P = 0.096). White circles denote treatment-naive patients, and black squares denote 
controls. n = 6 treatment-naive patients and 4 controls for which there were remaining samples available. Data represent mean ± SEM. Statistical 
significance was determined with Student’s 2-tailed t tests with Benjamini-Hochberg multiple hypothesis correction, with *α = 0.05, as appropriate.
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The stratifying naive CD4 T cells and classical monocytes (i.e., subsets with increased p-STAT1 and/
or p-STAT3 in patients compared with controls) were heterogeneous with varying expression levels of  
different surface markers. This is reminiscent of  recent work using mass cytometry that demonstrated that 
synovial T cell infiltrates in rheumatoid arthritis were highly heterogeneous and that characterization of  
the CD4 T cell diversity facilitated potential discrimination of  pathogenic and nonpathogenic variants of  
known T cell subsets (37, 38). Similarly, NK cell heterogeneity identified with mass cytometry was shown 
to contribute to West Nile virus susceptibility (39, 40).
While STAT1 phosphorylation is the canonical response to IFN, STAT3 phosphorylation can be 
coupled with STAT1 phosphorylation following IFN-γ stimulation (41). The ability of  IFN-γ stimula-
tion to phosphorylate STAT3 is demonstrated by the more pronounced and prolonged STAT3 phos-
phorylation following IFN-γ stimulation in murine STAT1-null cells compared with wild-type cells 
(41). Flow cytometry studies in a subset of  our patients found that both p-STAT1 and p-STAT3 basal 
levels were higher in JIA patient than control naive CD4 T cells and confirmed the mass cytometry find-
ing of  increased p-STAT3 following IFN-γ stimulation. No changes in IFNGR1 or PIAS1 expression 
were detected via flow cytometry, but patient naive CD4 T cells had higher levels of  JAK1 and SOCS1 
than control cells, although the magnitude of  these differences was not large. JAK1 is essential for phos-
phorylating STAT proteins, and elevated levels of  JAK1 may contribute to a greater phosphorylation 
of  STAT1/STAT3 in response to IFN-γ stimulation, while elevated levels of  SOCS1 in patients may 
represent a compensatory feedback mechanism.
The enhanced STAT1 and/or STAT3 phosphorylation following IFN-γ stimulation correlated with 
increased CD4 T cell and classical monocyte proliferation (assessed by Ki-67 expression) in treatment-na-
ive patients compared with controls, although CD4 T cell proliferation levels were very modest. There is 
evidence in murine studies that IFN-γ can enhance the proliferation and survival of  CD4 T cells (42, 43). 
Interestingly, Ki-67 expression was higher in both stratifying and nonstratifying subsets of  CD4 T cells and 
classical monocytes.
While insights into IFN-γ signaling differences in treatment-naive polyarticular JIA patients were 
gained from this work, there were several limitations, including the number of  patients studied and 
the number of  available PBMCs. The study included 17 treatment-naive samples from two centers and 
highlights the need for increased cooperation between centers to acquire large enough patient popula-
tions to allow new-onset, treatment-naive polyarticular JIA patients to be interrogated in a statistically 
meaningful manner. The number of  stimulations and time points was also constrained by the sample 
size. Mass cytometry helps mitigate this limitation by maximizing the data extracted from small bio-
logical samples, but subtler differences in signaling may be detectable with a larger cohort and more 
stimulation conditions and time points.
This study highlights the utility of  mass cytometry coupled with multiparameter phospho-specific 
antibodies in analyzing signal differences in small-volume patient samples. Using this approach, dif-
ferences in STAT1 and/or STAT3 phosphorylation in subsets of  CD4 T cells and classical monocytes 
following IFN-γ stimulation were identified in treatment-naive polyarticular JIA patient compared with 
control samples. The enhanced responsiveness of  CD4 T cells to IFN-γ stimulation correlated with 
increased expression of  JAK1 and SOCS1 in treatment-naive JIA patients. These results suggest that 
drugs that attenuate IFN-γ signaling (e.g., JAK inhibitors) may be useful in treating polyarticular JIA 
patients and provide a potential mechanistic rationale for anecdotal observations regarding the effective-
ness of  JAK inhibitors in refractory polyarticular JIA patients (including the case series of  3 refractory 
polyarticular JIA patients treated with tofacitinib, a JAK inhibitor, in the Supplemental Data) and for 
an ongoing clinical trial (NCT02591434) of  tofacitinib in polyarticular JIA patients. Interestingly, one 
of  patients in the case series (case 2) was included in the mass cytometry analysis as a treatment-naive 
sample (patient 7 in Table 1), and a follow up sample was subsequently obtained while the patient was 
in clinical remission on tofacitinib (after completion of  the initial analysis). Naive CD4 T cell p-STAT1 
and p-STAT3 following IFN-γ stimulation were lower in the remission sample while on tofacitinib (as 
well as leflunomide and hydroxychloroquine) compared with the paired treatment-naive samples (Sup-
plemental Figure 13). Future studies will focus on more detailed interrogation of  specific CD45RA+ 
CD4 T cell subsets to help us further understand mechanistically the increased IFN-γ responsiveness in 
subsets of  CD4 T cells in this disease.
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Methods
Patient cohort. Polyarticular JIA patients diagnosed in our pediatric rheumatology clinics were eligible for 
enrollment if  they were new onset and treatment naive. Samples were also collected from 10 of  the patients 
after achieving clinical remission, as defined by the Wallace criteria (without the use of  erythrocyte sedi-
mentation rate [ESR] or C-reactive protein [CRP]). The Wallace criteria define clinical remission as having 
no joints with active arthritis; physician global assessment of  disease activity indicating clinical disease 
quiescence; no active uveitis; no fever, splenomegaly, rash, serositis, or generalized lymphadenopathy; 
and normal ESR or CRP (8). Seven of  the seventeen treatment-naive patients had either not achieved 
clinical remission at the time of  the study analysis or had no available follow-up samples. PBMCs from 
treatment-naive polyarticular JIA patients and controls were also utilized from the Cincinnati Children’s 
Hospital Medical Center Pediatric Rheumatology Tissue Repository and the Cincinnati Genomic Control 
Cohort. Given the relatively small number of  treatment-naive polyarticular JIA patients in this study and 
recent evidence demonstrating minimal differences in microarray data between RF+ and RF– polyarticular 
JIA PBMCs (29), we did not further subset our polyarticular JIA patients into RF+ and RF– patients.
Reagents. Antibodies conjugated to heavy metals were purchased from Fluidigm, with the exception 
of  CD69 (Biolegend, Supplemental Table 1). Antibodies for flow cytometry were purchased from multiple 
vendors (Supplemental Table 2).
Sample preparation and collection. Blood samples were collected from 17 treatment-naive, new-onset poly-
articular JIA patients; a follow-up sample was collected when 10 of  the 17 JIA patients were in clinical 
remission on medication; and samples were collected from 19 controls (Table 1), and PBMCs were isolated 
using a Ficoll gradient (GE Healthcare) and cryopreserved.
Mass cytometry. PBMCs were thawed and stained with cisplatin to discriminate dead cells (Fluidigm). 
Cells were aliquoted (1.7 × 106 to 3.3 × 106 cells/tube) in 1-ml total volume and rested for 30 minutes at 
37°C prior to simulation. Cells were either left unstimulated or were stimulated with 50 ng/ml IL-6 or 
250 ng/ml IFN-γ (PBL) for 15 minutes in RPMI1640 supplemented with 10% fetal calf  serum at 37°C, 
fixed with MaxPar Fix I Buffer (Fluidigm), permeabilized with MaxPar Barcode Perm Buffer (Fluidigm), 
and barcoded with the Cell-ID 20-Plex Barcoding Kit (Supplemental Table 3; Fluidigm). Barcoded sam-
ples were pooled and stained with antibodies for surface markers. After staining for surface markers, 
the pooled samples were methanol permeabilized and stained with antibodies for intracellular markers 
(Supplemental Table 1). Samples were incubated with Cell-ID Intercalator-Ir (Fluidigm) to detect debris 
and doublets, and run on a CyTOF2/Helios instrument (Fluidigm). Samples were debarcoded using 
the Single Cell Debarcoder, a stand-alone MATLAB application (44). Data were analyzed using Cyto-
bank and R. A run control from the same normal donor was used in each experiment to normalize the 
phosphoprotein data as follows:
asinh(xsample/5) – asinh(xRun Control/5), where x represents raw median signaling intensity for each phosphor-
ylated signaling molecule in a specific immune cell subset and asinh represents the inverse hyperbolic sine.
Citrus. Citrus, a computational technique combining hierarchical clustering with an analysis of  strat-
ifying differences in cluster features (in our case, phosphorylation of  a panel of  signaling proteins within 
specific immune cells) between two groups of  samples, was performed with the R “citrus” package on fcs 
files gated on live immune cells to compare treatment-naive patients with matched controls (or remission 
samples) under different stimulation conditions (45). Surface markers were clustering parameters. Mini-
mum cluster size was set as 2% of  the total population with 10,000 events sampled per file. Cluster char-
acterization features were signaling molecules. All clustering and characterization features were arcsinh 
transformed. Differences in cluster features were calculated using SAM. A FDR of  5% was set as a cutoff  
for significance (q < 0.05).
To delineate which subsets of  cells responded differently between treatment-naive patients and con-
trols, deeper analysis of  surface markers on stratifying (significantly different signaling molecule phos-
phorylation between patients and controls for a given cluster) versus nonstratifying clusters for p-STAT1 
and p-STAT3 was performed. All surface markers were analyzed. A trio of  clusters containing three con-
nected nodes in which there were two stratifying clusters and one nonstratifying cluster were examined 
to determine which surface markers contribute to a cluster being stratifying or nonstratifying. Surface 
marker intensity for clusters was also visualized as a colored hierarchical clustering tree as well as plots 
of  median surface marker intensity for all stratifying and nonstratifying classical monocyte and naive 
CD4 T cell clusters.
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Flow cytometry. To further investigate potential mechanisms causing differences in IFN-γ signaling poten-
tial, flow cytometry experiments were performed with a subset of  6 treatment-naive patients (for which there 
were remaining samples available) and 4 control samples from the samples collected at the host site. Samples 
(0.5 × 106 to 1 × 106 cells/sample) were left unstimulated or stimulated 15 minutes with 250 ng/ml IFN-γ and 
fixed with BD Cytofix/Cytoperm buffer. Samples were stained with one of  several antibody panels (Supple-
mental Table 2). Flow cytometry was performed on a 12-color LSRFortessa X-20 Flow Cytometer (BD) and 
analyzed with FlowJo (FlowJo). Classical monocytes and naive CD4 T cells were gated and analyzed for 
differences in components of  the IFN-γ signaling cascade between patient and control samples.
Statistics. One-way ANOVA with Bonferroni’s multiple comparisons test between all patient and con-
trol samples was used to test differences in the distribution of  immune cell subsets between treatment-naive 
patients and controls (46). A paired 2-tailed Student’s t test with Benjamini-Hochberg multiple hypothesis 
correction was used to analyze paired treatment-naive and remission patient immune cell percentages. SAM 
was used to explore differences in signaling phenotype in various types of  PBMCs. Differences detected by 
SAM were confirmed with unpaired 2-tailed Student’s t tests and Benjamini-Hochberg multiple hypothesis 
correction. To determine which PBMC subsets drove differences detected in SAM, live cells were analyzed 
via Citrus with SAM to classify differences distinguishing patients and controls, and results were confirmed 
using unpaired 2-tailed Student’s t tests with Benjamini-Hochberg multiple hypothesis correction. Differ-
ences in surface marker expression between trios of  clusters with two stratifying and one nonstratifying 
were analyzed with ANOVA and a Dunnett’s test in relation to a singular nonstratifying cluster. Classical 
monocyte and naive CD4 T proliferation differences were tested for both gated populations and Citrus 
clusters with an unpaired 2-tailed Student’s t test and Benjamini-Hochberg multiple hypothesis correction. 
To analyze flow cytometry data, 2-tailed Student’s t tests with Benjamini-Hochberg multiple hypothesis 
correction were used to test the hypotheses that there are differences in STATs (p-STAT1 and p-STAT3), 
IFNGR1, JAK1, and inhibitory proteins in cells (SOCS1 and PIAS1). An α value of  0.05 was used to deter-
mine significant P values with multiple hypothesis correction as appropriate.
Study approval. This work was approved by the institutional review boards at Washington University 
School of  Medicine and Cincinnati Children’s Hospital. Polyarticular JIA was defined according to the 
International League Against Rheumatism criteria for classifying idiopathic arthritis of  childhood (22). 
Written informed consent was received from participants prior to inclusion in the study.
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